Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Cytokinetics advances obstructive HCM treatment with strong financials and strategic focus

Cytokinetics is poised for growth with FDA submission for aficamten and strong financial position.
Strategic focus on commercial preparations and clinical trials signals a commitment to future success.
Challenges in market competition and education require targeted efforts for successful product launch.
Emphasis on patient-centric approach and category expansion positions the company for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA's language in its recent briefing document for Cytokinetics' omecamtiv mercabil is a key factor to scrutinize. The FDA panel voted in a majority that the benefits may not outweigh the risks for the omecamtiv compound in its target population.

Where To Now With Cytokinetics After The Omecamtiv Outcome?

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco.

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.

Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting

A "bruising" FDA meeting for Cytokinetics was actually a blessing in disguise, an analyst said Wednesday as CYTK stock surged. The post Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug appeared first on Investor's Business Daily.

Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug

PDUFA Target Action Date is February 28, 2023

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

FDA Advisory Committee to Review the New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction FDA Advisory Committee to Review the New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction

Cytokinetics Stock Trading Halted Today

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score  Strongly Correlated with Decline in ALSFRS-R

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33r d International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction (HFrEF) from the Get With The Guidelines®-Heart Failure Registry, were presented at the American Heart Association Scientific Sessions 2022 in Chicago, IL.

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Andrew Callos - Executive Vice President & Chief Commercial Officer Stuart Kupfer - Senior Vice President & Chief Medical Officer Robert Wong - Vice President & Chief Accounting Officer Ching Jaw - Senior Vice President & Chief Financial Officer Conference Call Participants Carter Gould - Barclays Yasmeen Rahimi - Piper Sandler Joe Pantginis - H.C. Wainwright.

Cytokinetics, Incorporated (CYTK) Q3 2022 Earnings Call Transcript

Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022;  PDUFA Target Action Date Set for February 28, 2023

Cytokinetics Reports Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7, 2022. The poster presentations include an analysis of patients hospitalized for heart failure with severely reduced ejection fraction from the Get With The Guidelines®-Heart Failure Registry as well as two analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one relating to healthcare resource use, early benefit, and cost for North American patients most likely to benefit from treatment with omecamtiv mecarbil, and one assessing sex differences in GALACTIC-HF.

Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022

Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.

Cytokinetics CEO: Why It's OK Not Being An Overnight Success

The FDA Advisory panel is expected to review Cytokinetics' omecamtiv mecarbil for the treatment of patients with heart failure on December 13, 2022. The FDA PDUFA date of omecamtiv mecarbil for the treatment of patients with heart failure is set for February 28, 2023.

Cytokinetics: 2 Catalysts For Heart Failure Drug Make This Worth A Look

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce Third Quarter Results on November 3, 2022

The FDA announced a surprise advisory committee meeting for Cytokinetics, Incorporated's omecamtiv, on December 13. Omecamtiv is not Cytokinetics' best asset.

Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern

Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.

Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?

Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.

Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv

Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023 Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023

Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases

News for Cytokinetics Stock (CYTK)